Benjamin Besse
@benjaminbessemd.bsky.social
Medical Oncologist - Lung cancer, thymic tumors & NUT carcinomas.
Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC.
Messages reflect my own opinion.
Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC.
Messages reflect my own opinion.
Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront?
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
March 26, 2025 at 4:44 PM
Debate on L1 for EGFR mut NSCLC : ‘easy osi’ then escalate to CT-ami, or use doublet upfront?
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
Lazertinib+amivantmab likely to extend OS by ~ 1 yr vs osimertinib, but without cross over to CT-ami.
Intensify only if ctEGFR not cleared after 4w of osi? #ELCC25
What can a test that identifies all previous viral infections in patients with lung cancer reveal about immunotherapy efficacy?
#LCSM
bit.ly/4fNuDDw
#LCSM
bit.ly/4fNuDDw
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
Introduction Immune checkpoint blockers (ICBs) revolutionized the treatment of patients with advanced non-small cell lung cancer (NSCLC) but only a fraction of them obtain a response, and clinical ben...
bit.ly
December 3, 2024 at 6:49 PM
What can a test that identifies all previous viral infections in patients with lung cancer reveal about immunotherapy efficacy?
#LCSM
bit.ly/4fNuDDw
#LCSM
bit.ly/4fNuDDw